text:
Attractive, intuitive interface. Tons of useful tools and filters. Affordably priced. Sharing options. Graphic tablet support.
Wealth of options may intimidate novices. No zoom slider option. Some trouble with Photoshop layers.
Pixelmator brings varied and flexible photo-editing features to the Mac at a very wallet-friendly price. Pixelmator isn't as deep as Adobe Photoshop CS5—and it isn't trying to be—but it's still a very capable image editor that's cheaper than Adobe Photoshop Elements, and packs more power than Picasa and Picnik.
Pixelmator Team dubs its Mac OS X photo editor as "image editing for the rest of us," and it's quite easy to understand why. The $29.99 application (which is available for purchase in the Mac App Store) is a low cost, affordable Adobe Photoshop CS5 ($699, 5 stars) alternative that comes packed with an array of tools that let you edit and enhance BMP, JPG, TIFF, PNG, and other files using painting tools, layers, color correction, and over 130 included filters. In fact, it's even cheaper than the Editors' Choice award-winning Adobe Photoshop Elements ($99.99, 4 stars). It doesn't possess some of Photoshop's more advanced features, or iPhoto '11's ($14.99, 4 stars) image organizer and more "fun" features, but it's a robust and wallet-friendly option for those who want something deeper than Microsoft Paint.
Design and InterfaceYou're presented with three options when you launch Pixelmator: Create New Image, Open Existing Image, and Open Recent Image. Create New Image lets you open a photo at a preset size (ranging from 640 x 480 to 1920 x 1200, as well as various dimensions), or customize your own size. Open Existing Image is your standard way of opening a file. The self-explanatory Open Recent Image launches a drop-down menu that lets you select a recently opened photo. All three beginning steps worked without a hitch.
The Image Editing ExperienceBut those who are willing to roll up their sleeves and dig in will find Pixelmator a stacked photo editor. Familiar tools such as the rectangle and lasso selection tool are here as well, as more advanced options such as Gradient Tool (which drops a colored, rotatable gradient within a selected area) and Paint Bucket, which can be used to fill the portion of (or entirety of) a section by moving the mouse incrementally. Pixelmator includes touchup tools such as Blur, which softens portions of the image. Working in tandem with different brush sizes, you can get really creative with your work; Magic Wand, for example, is extremely flexible as it lets you quickly remove portions of the image, or to transfer them to another image. Clone is decent for touch ups, as it let me copy a highlighted part of an image and paste it elsewhere, but Photoshop Express' Healing Brush makes for a more lifelike copy, especially in regards to skin tone. This is great for removing blemishes. As a non-pro or hobbyist, I found it relatively simple to jump in and experiment, but I've dabbled in these more advanced editors before. I liked that I could click the Full Screen icon that blacked out my starry background, enabling a distraction free editing environment.
Pixelmator includes the standard brushes, text editor, and colorization tools that you'll find within other image editors, and, like Photoshop Elements, it supports layers. In fact, you can fire up a Mac's built in iSight camera to snap photos that can be applied as a layer onto another. This lets you do a lot of things with an image that aren't possible in many free photo editors such Picnik (Free, 3.5 stars), which lack layering. There are also tons of visual filters for quickly adding a special touch to photos such as Motion Blur (which adds speed lines), and Pixelate (which gives photos the 8-bit computer/video game graphics look). Pixelmator also supports Line and Curves for those that like to tinker with such options, but lacks Photoshop's Content-Aware Fills. Then again, if you really need that feature, chances are that you're a high-level editor who won't do without Adobe's monster suite.
Adding effects in Pixelmator, for the most part, was as simple as setting effect intensity and applying it to the image, but more skillful edits, such as layering, required multiple steps and may demand that novices seek instruction. Still, it could've benefitted from the addition of a zoom slider, a tool found in iPhoto '11; personally, I was fine with the Command and + control, but there are undoubtedly others who'd prefer a slider.
Pixelmator supports graphics tablets, and is compatible with JPEG, TIFF, PNG, PDF, and other files. You can also import Photoshop files that have layers, but it has some difficulty accurately displaying them. Photoshop Elements, as expected, doesn't have such issues, so you may want to invest in that if you want to future-proof yourself in case you move on up to CS5.
Sharing You can share your images by clicking File > Send To, which opens options that let you email the file to others, send it to iPhoto or Aperture, or upload to Flickr, Facebook, and Picasa. I shared a few photos to friends via Facebook without issue. You may want to do that if you plan on storing photos as the app lacks an organizer—something that more consumer-friendly apps such as iPhoto '11 possesses. In addition, iPhoto '11 and Photoshop Elements let you transform your snaps into physical items such as cards, photo books, and other smile-inducing creations.
Should You Buy Pixelmator? If you want to edit images in a Photoshop-light like manner, the $29.99 Pixelmator will let you do so for hundreds of dollars less than Adobe's full-sized product, Photoshop CS5, and a few less than Photoshop Elements. Granted, if you're not accustomed to what this program offers, you'll encounter a significant learning curve in comparison to Picasa or Picnik. Still, it's one of the best photo apps you'll find on your Mac outside of Adobe's powerhouse and worth consideration if you're looking to dive deeper than what Paint offers.
More Image Editing Reviews: Facetune 2 (for iPhone) Adobe Photoshop CC Google Photos (for Android) Ashampoo Photo Commander ACDSee Ultimate more
PCMag may earn affiliate commissions from the shopping links included on this page. These commissions do not affect how we test, rate or review products. To find out more, read our complete terms of use.
For more than a decade, Jeffrey L. Wilson has penned gadget- and video game-related nerd-copy for a variety of publications, including 1UP, 2D-X, The Cask, Laptop, LifeStyler, Parenting, Sync, Wise Bread, and WWE. He now brings his knowledge and skillset to PCMag as Senior Analyst.
When he isn't staring at a monitor (or two) and churning out Web hosting, music, utilities, and video game copy, Jeffrey mentors, practices Jeet Kune Do, blogs, podcasts, and speaks at the occasional con. He also collects vinyl and greatly enjoys...
More »
The Pinball Arcade offers dozens upon dozens of faithfully recreated pinball machines, but acquiring...
More »
Packed with features, A2 is a Web hosting service that's more than worthy of being the foundation fo...
More »
Killer Instinct took a while to appear on PC, but the feature-packed fighter is worth the wait. Howe...
More »


text:
Hello Guest! You are browsing the forums as a guest; you will have limited permissions as a guest so we advise registering to enjoy the forums fully. Remember: we are a Christian ONLY site - any user who is not Christian will not be approved. Blessings, Christian Forum Site StaffDismiss Notice
Church: Bishop was communist spy - CNN International
Discussion in 'News and Articles' started by World news, Jan 5, 2007.

subset: commoncrawl


text:
Have Your Say
Submit a Review
Have you been to Moonriver Guest House in Upington?
Let us know what you thought of the venue and how you enjoyed your visit to Green Kalahari.
Quick Facts
GPS location
Latitude: -28.45776
Longitude: 21.248555999666667
Closest airport(s)
Upington Airport - 10km
Children policy
Children of all ages are welcome.
Check-in/out times
Check-in from 14h00
Check-out by 10h00
Listed on SA-Venues.com
December 2009 - No guest reviews.


text:
NEW BRUNSWICK - Four more Rutgers University students face charges stemming from a rowdy street party last month where people brawled and set couches and mattresses on fire.
New Brunswick Police announced Tuesday that they have criminally charged eight students overall and issued 16 additional summonses.
The charges include aggravated assault on police, disorderly conduct, weapons offenses, riot and arson. Seven of the students are from New Jersey and one is from Virginia.
More than 500 people were at the bash on April 13 that students dubbed "Delafest."
New Brunswick police had arrested three students while breaking up the party and Rutgers police arrested one. No injuries were reported.
Authorities have said officers were hit by bottles allegedly thrown by partygoers, and people set furniture on fire. Photos and video show police in riot gear carrying pepper spray.


text:
Where o' where are the Reel Blues? The band has been on the radar for years, but I still haven't nailed down where the Reel Blues called home.
Here's hoping that someone can identify the place the two pics were taken. Many people contributed pics and info over the years, but most of my handwritten notes prior to 2009 were lost in the flood that washed out the 60's indiana band szene central command. Thankfully, I'm pretty fanatic about digital copies and backups!
As the usual plea goes, any info about the Reel Blues, feel free to chime in!
And Happy Thanksgiving to you and yours!
Wednesday, November 23, 2016
Friday, September 30, 2016
Tyrone & the Upsetters - Ft. Wayne - Gateway Records
Ok, let's get back in the groove! I've been away for quite a bit, and even contemplated just erasing this whole thing. But what the hell, complainers be damned, full speed ahead.
Tonight we present "Tyrone & the Upsetters" from beautiful
Ft. Wayne. The only names I've ever found associated with the band are:
Don Ganaway
Thomas Brownlee ( I believe he is the second from left in the pic).
The Upsetters released a 45 on Gateway Records, which has Ft. Wayne listed on the label. I'm almost certain Gateway was a label promoted by a department store in the area. The Upsetters check in at #308 and I also have a 45 of the Impostors (sic) at #333. So could there be 33 or more releases on the label, or just some oddball numbering? We may never know........
So the fans are waiting for the tunes, right? Let's hear 'em now!
Running Hot - credited to the Upsetters
That's Not Love - Tyronne & the Upsetters
Tyronne is the spelling on the label, but the promo pic shows Tyrone. I'm just glad I can track it that far. Any other info gladly accepted!
Posted by vinylfool at 8:22 PM 2 comments
Saturday, January 23, 2016
Cavaliers - Greenwood
From the files of "60's indiana band szene" Central Command, we find the Cavaliers of Greenwood. I recently found a photo of the Cavaliers while looking thru yearbooks (a great way to find a few band photos!), in this case from Indian Creek High School 1965.
The Cavaliers were together for a few years - the yearbook shows a homecoming dance, so that would be late 1964. Most probably some frat rock and early Beatles would keep the kids happy on the dance floor.
I can document the Cavaliers playing thru at least March 1967 - that would be from the Whiteland Barn ad. After that.......?
Members included (photo above):
Fred Kinnan - lead guitar
Allen Martin - rhythm guitar
Dick Tyndal - tenor sax
Mike Langford - bass
Gary Scott - drums
and later
Ed Weddle - hammond organ
Roger Craighead replaced Mike on bass
Sam Doolin - trumpet - vocals
Special thanks to Gary for the band info!
Posted by vinylfool at 11:01 PM 2 comments
Monday, December 14, 2015
Klockwork Orange - Aug. 1968
Blair Austin,
Mike Bishop,
Chandler Sammons,
Robin Raub,
Dan Evard,
and Scott Hoffman.
Introducing the "Klockwork Orange". And now if we could just get an update on how the battle went!
Posted by vinylfool at 8:15 PM 0 comments
Monday, November 30, 2015
Anne and the Henchmen 1966
Presenting for your amusement:
Anne & the Henchmen, January 1966.
What can we deduce from the photo? Anne Hall is the singer, and maybe in charge of wardrobe and make-up. Ducan (Duncan?) Williams is the drummer, Mike Schevrer is gripping that bass. Moving on to Bob Stavton, posing with a cute little fender, and that leaves Dave O'Guinn, maybe looking for his organ or perhaps peeved that Anne took his singing gig.
It's all speculation, but we're glad they performed and maybe someone will check in!
Posted by vinylfool at 7:23 PM 1 comments
Tuesday, October 27, 2015
Minutemen - 1966 Chatrand High School
The Minutemen won 1st prize at the variety show competition in late 1965. The photo appeared in the Indianapolis Star on Jan. 8th, 1966 (Elvis' Birthday!) with about 20 other bands listed.
Left to right:
Dave Stonehouse
Steve Stonehouse
Tom Arnold
Phil Eaton
Any of these guys go on to bigger or better things? As always, any info is delightfully received.
Now for the other 799 bands...........
Posted by vinylfool at 8:06 PM 0 comments
Saturday, September 5, 2015
Boys Next Door - Reunion show - Sept. 19th 2015
Short notice - but it slipped thru the cracks here at 60's indiana band szene central command. Spread the word! And think a good thought for the memory of Steve Drybread. Look forward to meeting new friends there.
Posted by vinylfool at 1:31 PM 0 comments
Subscribe to: Posts (Atom)


text:
Who is this project for? Women What are you most proud of? I enjoyed doing something different and a little out of my usual style. What advice would you give someone starting this project? This is an easy project that can be done in less than an hour. Be sure to get the loop behind the discs pretty tight to the discs or the discs will droop forward.
No completed Q&As yet.


text:
Secrets are usually a very ad thing when dating. And 99% of us will jump to the worse case scenario when we hear the phrase: "there's something i didn't tell you." But for the first time EVER, a confession turns out be so good, it's like hitting the dating lottery!Read More »
Second Date Update ™
Second Date Update PODCAST: Mr. Funny Pants
Sometimes, when some women don't like a guy and if they DON'T want to go out with him again… They just ASSUME he's going to take the hint. But most of the time, he doesn't. Especially our Second Dater Jamie… he CANNOT take a hint… He can't even take the TRUTH! Listen to the podcast.Read More »
Second Date Update PODCAST: Crazy for Mother Nature
Is there ANYTHING more sensual and soothing, than the beautiful sounds of nature, playing gently in your ear drums, as you bike through a sunny meadow? But all of it gets RUINED by one simple thing. And for Veronica, it's a huge deal breaker.Read More »
Second Date Update PODCAST: Baby Got Flat
Everyone has a list of deal breakers for dating… They're too short, they work too much, they don't want kids… There are several reasons to explain why a date just won't work out. But the guy in this Second Date Update has a deal breaker that is seriously the strangest we have ever heard… We don't think there is one …Read More »
Second Date Update PODCAST: Honk It Out
This Second Dater is a total badass… He got kicked out of a store AND vandalized private property all while on a DATE with a girl… And believe it or not, that's NOT why he isn't getting a call back from her. The REAL REASON is even crazier than all of those. Find out what it was by listening to the …Read More »
Second Date Update PODCAST: Fake & Fantastic
How many excuses do yo have to hear from someone about being "too busy", before you get the hint that they just don't like you? One of our listeners emailed the show after SHE got blown off five times by the same guy... and the reason si something none of us could have imagined.Read More »
Second Date Update PODCAST: Passion Partners
One of our listeners called us because he couldn't see why a woman he met on an online dating site refuses to go on a second date with him… So we went ahead and gave her a call… And it turns out she was so UPSET after their date that she NEVER will do online dating again. Find out what went so …Read More »
Second Date Update PODCAST: British Guy Ditched and Dismissed
In this morning's Second Date Update, we had a SPECIAL case where a guy with a sexy foreign accent is calling us for help because he can't get a call back from an American girl… Usually it's the other way around, isn't it? Listen to the podcast to hear the ridiculous reason WHY he won't get a call back!Read More »
Second Date Update PODCAST: Micro Naps
When we heard the reason why our 2nd dater didn't get a call back… We couldn't believe it. We're not sure how he could POSSIBLY think that he deserves a second chance… Because there is NO WAY that ANYBODY could be okay with what he did on his first date… Let alone ANY date! Find out what he did by listening …Read More »
Second Date Update PODCAST: Pillow Talk
What is the worst thing that could happen, if you drunkenly hooked up with one of your good friends?... Whatever you thought of, it's not NEARLY as bad as what happened in today's Second Date Update.Read More »


text:
Big baby
I am prego with baby #2 and my first was 8lbs 13oz. I was wondering if ya'll have had babies around the same size or if each has been really diffent. My mom had 3 7-11, 7-2 and 6-9 and my friend just had her second and he was a pound and an oz bigger than her first. Just wondering what everyone else has experianced.
Posted: 08/21/2012 by kristinemarques
Mom Answers
Sort by: best answers | most recent answers
1 - 2 of 2 answers
1st baby was 5lb 8 oz i was 3 weeks and 2 days early my 2nd was 6lb 6oz i was 3 weeks 5 days early, I'm now pregnant with our 3rd i cant wait to see how much he weighs :-) I think most children weight about the same area, but i dont know...posted 08/21/2012 by Lovebug_3
#1- 8lbs 5oz at 40+1, #2 - 8lbs 5oz at 39+5, #3 - 9lbs 2oz at 39+6, #4 - 9lbs 2oz induced at 39+1posted 08/21/2012 by a BabyCenter Member
Answer this question


text:
Lovely couple is having passionate missionary style sex in high quality video
Tags: beauty blondes couple cute girlfriend hardcore missionary
Hot couple having good sex in their office-Augusta busty blonde slut sucks dick blowjob and fuck creampie cumshot facial Hot couple having good sex in
Tags: blondes blowjobs busty couple creampie cumshots dick
Lovely young couple having making love gently
Tags: amateur brunettes couple teens
This couple likes having hard anal sex, but most of all they like having hard anal sex on camera. Enjoy the steamy action!
Tags: anal ass assfingering blondes couple doggystyle hardcore
Lovely Sandra Having Anal Sex
Tags: anal
Lovely couple enjoying a hardcore reality sex
Tags: big tits blowjobs boobs brunettes couple cowgirl cum
Lovely Couple enjoying Anal sex at home
Tags: anal babes blowjobs brunettes couple cumshots doggystyle
Lovely blonde having steamy anal sex
Tags: amateur anal blondes
Lovely horny couple gets wild in hardcore reality sex
Tags: ball licking big tits blowjobs brunettes couple doggystyle hardcore
Hardcore Sex By Lovely Couple And Barebacking Action Scene
Tags: barebacking couple gays hardcore
Lovely couple steamy kiss and make up romantic sex
Tags: babes blowjobs brunettes couple creampie hardcore hd
Horny couple is having passionate oral sex in amateur sex tape
Tags: amateur blowjobs couple homemade indian oral sex tape
Lovely cougars having a cute lesbians threesome sex
Tags: backstage big tits cute fake tits lesbians milf reality
Lovely angel with appetizing titties having passionate sex
Tags: beauty blowjobs brunettes cute hardcore licking pussy
Lovely brunette teen having first time anal sex
Tags: anal beauty blowjobs brunettes doggy first time missionary
Two lovely girls having sex on red couch
Tags: babes lesbians pussy toys
Hardcore sex video with a couple having oral sex in the shower
Tags: babes bathroom beauty blowjobs brunettes busty couple
Sensual couple having passionate doggy style sex in high quality sex video
Tags: beauty blowjobs brunettes couple cute doggy hardcore
Unforgettable sex in the living room for this lovely couple
Tags: babes blowjobs brunettes couple girlfriend hairy hardcore
Lovely Japanese cutie gives superb POV blowjob in couple sex
Tags: asian blowjobs couple cumshots hardcore japanese pov
Couple having sex
Tags: amateur brunettes couple doggystyle
Couple Having Sex
Tags: anal blowjobs couple
couple having sex
Tags: amateur couple hardcore oral
TrafficHolder.com - Buy and Sell Adult Traffic|Trafficshop.com - Let your business grow|Contact Us|Webmaster
All content, including images, text, graphics, video and audio content contained in the website is protected under the laws of copyright, owned or under license to company or its designees,and represents proprietary and valuable intellectual property.
Contact Webmaster 18 U.S.C. 2257 Record-Keeping Requirements Compliance Statement
Powered by Stream Rotator


text:
Home /
Our Sources / About Us
/ FAQs /
Advanced Search
Not what you're
looking for? Try an advanced search.
Official citation and/or docket number and footnotes (if any) for this case available with purchase.
Learn more about what you receive with purchase of this case.
May 19, 2010
MICHAEL PENNY, PLAINTIFF,v.U.S. DEPARTMENT OF JUSTICE, DEFENDANT.
Re Document No. 22
In this civil action brought pro se under the Freedom of Information Act ("FOIA"), 5 U.S.C. § 552, the plaintiff challenges the United States Marshals Service's ("USMS") response to his requests for records pertaining to himself, other individuals and real property. In a prior memorandum opinion, the court denied in part without prejudice the defendant's motion for summary judgment, concluding that the defendant had not demonstrated that the USMS had conducted an adequate search for records in a particular database in response to the plaintiff's FOIA requests. The defendant now renews its motion for summary judgment as to the adequacy of its search. Upon consideration of the parties' supplemental submissions, the court grants the defendant's renewed motion.
The plaintiff commenced this action in September 2008, challenging the USMS's response to his requests for records pertaining to himself, the execution of a search warrant on August 16, 2006 at 4901 W. Congress Street in Chicago, Illinois, a lease agreement "between the Federal Government & Michael Penny, on or about . . . April of 1989" for the aforementioned property and "any and all records or documents" pertaining to the leasing and occupancy of said property by the plaintiff, Tammy Brown and unnamed individuals during the 1990s.*fn1 Def.'s Renewed Mot. for Summ. J., Decl. of William E. Bordley ("Bordley Decl."), Ex. A. In December 2008, the defendant moved for summary judgment. See generally Def.'s 1st Mot. for Summ. J.
The court issued a memorandum opinion in September 2009, granting in part and denying in part without prejudice the defendant's motion for summary judgment. See generally Mem. Op. (Sept. 15, 2009). Specifically, the court granted summary judgment to the defendant on its claim that certain FOIA disclosure exemptions justified the nondisclosure of certain materials otherwise responsive to the plaintiff's requests. Id. at 5-6. The court, however, denied without prejudice the portion of the defendant's motion concerning the adequacy of the search conducted in response to the plaintiff's request. Id. at 6-8. The court specifically noted that the defendant had searched its Consolidated Assets Tracking System ("CATS") database only by using an "asset identification number," rather than other retrieval terms, such as the plaintiff's name and personal identifier, that it had used when searching other databases potentially containing responsive documents. Id. at 6. Because the defendant had provided no basis for concluding that its search of the CATS database was reasonably calculated to locate all responsive records, the court denied without prejudice the defendant's motion for summary judgment on this search. Id.
In October 2009, the defendant filed this renewed motion for summary judgment. See generally Def.'s Renewed Mot. for Summ. J. With this renewed motion fully briefed, the court turns to the applicable legal standards and the parties' arguments.
A. Legal Standard for a Motion for Summary Judgment
Summary judgment is appropriate when "the pleadings, depositions, answers to interrogatories, and admissions on file, together with the affidavits, if any, show that there is no genuine issue as to any material fact and that the moving party is entitled to a judgment as a matter of law." FED. R. CIV. P. 56(c); Celotex Corp. v. Catrett, 477 U.S. 317, 322 (1986); Diamond v. Atwood, 43 F.3d 1538, 1540 (D.C. Cir. 1995). In deciding whether there is a genuine issue of material fact, the court is to view the record in the light most favorable to the party opposing the motion, giving the non-movant the benefit of all favorable inferences that can reasonably be drawn from the record and the benefit of any doubt as to the existence of any genuine issue of material fact. Adickes v. S.H. Kress & Co., 398 U.S. 144, 157-59 (1970). To determine which facts are "material," a court must look to the substantive law on which each claim rests. Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 248 (1986). A "genuine issue" is one whose resolution could establish an element of a claim or defense and, therefore, affect the outcome of the action. Celotex, 477 U.S. at 322; Anderson, 477 U.S. at 248.
FOIA affords the public access to virtually any federal government record that FOIA itself does not specifically exempt from disclosure. 5 U.S.C. § 552; Vaughn v. Rosen, 484 F.2d 820, 823 (D.C. Cir. 1973). FOIA confers jurisdiction on the federal district courts to order the release of improperly withheld or redacted information. 5 U.S.C. § 552(a)(4)(B). In a judicial review of an agency's response to a FOIA request, the defendant agency has the burden of justifying nondisclosure, and the court must ascertain whether the agency has sustained its burden of demonstrating that the documents requested are exempt from disclosure under FOIA and that the agency has adequately segregated exempt from non-exempt materials. 5 U.S.C. § 552(a)(4)(B); Al-Fayed v. CIA, 254 F.3d 300, 305 (D.C. Cir. 2001); Summers v. Dep't of Justice, 140 F.3d 1077, 1080 (D.C. Cir. 1998); Mead Data Cent., Inc. v. Dep't of Air Force, 566 F.2d 242, 260 (D.C. Cir. 1977). An agency may meet its burden by providing the requester with a Vaughn index, adequately describing each withheld document and explaining the reason for the withholding. Summers, 140 F.3d at 1080; King v. Dep't of Justice, 830 F.2d 210, 224 (D.C. Cir. 1987); Vaughn, 484 F.2d 820 (fashioning what is now commonly referred to as a "Vaughn index").
The court may grant summary judgment to an agency on the basis of its affidavits if they:
[(a)] describe the documents and the justifications for nondisclosure with reasonably specific detail, [(b)] demonstrate that the information withheld logically falls within the claimed exemption, and [(c)] are not controverted by either contrary evidence in the record nor by evidence of agency bad faith. Military Audit Project v. Casey, 656 F.2d 724, 738 (D.C. Cir. 1981).
B. The Defendant Conducted an Adequate Search for Responsive Records
In support of its renewed motion, the defendant submits two declarations from William Bordley, Associate General Counsel and FOIA/Privacy Act Officer of the USMS.*fn2 See generally Bordley Decl.; Def.'s Renewed Mot. for Summ. J., Supplemental Decl. of William E. Bordley ("Supplemental Bordley Decl."). Bordley contends that the defendant conducted a search of its Prisoner Processing and Population Management/Prisoner Tracking System and the Warrant Information Network ("WIN") using the "plaintiff's name and/or personal identifier, [] asset identification number, and by reference to the items listed pursuant to his request." Bordley Decl. ¶¶ 5-7. This search covered the defendant's office in the Northern District of Illinois and the USMS Headquarters Asset Forfeiture Office. Id. ¶¶ 5, 7.
Moreover, Bordley states that in response to the court's September 2009 ruling, the defendant conducted an additional search of the CATS database. Supplemental Bordley Decl. ¶ 3. Specifically, Bordley states that on September 29, 2009, "the USMS CATS Team Leader performed searches for records using the following identifiers: 1. Michael Penny, 2. 4901 W. Congress Street, Chicago, Illinois [,] 3. Seizure Warrant No. 89 C 2736 and 4. Civil Case No. 89 C 2736." Id. ¶¶ 2-3. This supplemental search uncovered two additional pages of responsive records, which the defendant released to the plaintiff on October 6, 2009. Id. ¶ 6 & Ex. J. Bordley further states that "the USMS has conducted an exhaustive search in the databases and files . . . where information pertaining to plaintiff's FOIA request reasonably would be located." Id. ¶ 7.
In his opposition, the plaintiff questions the adequacy of the defendant's search and speculates that responsive records could be available elsewhere. See generally Pl.'s Opp'n. None of the plaintiff's unsubstantiated claims, however, "plac[es] the sufficiency of the identification or retrieval procedures genuinely in issue[.]" Spannaus v. CIA, 841 F. Supp. 14, 16 (D.D.C. 1993); see also Boyd v. Criminal Div. of U.S. Dep't of Justice, 475 F.3d 381, 390-91 (D.C. Cir. 2007) (reiterating that "the fact that a particular document was not found does not demonstrate the inadequacy of a search") (internal citations omitted); Campbell v. Dep't of Justice, 164 F.3d 20, 28 (D.C. Cir. 1998) (stating that "[w]hen a request does not specify the locations in which an agency should search, the agency has discretion to confine its inquiry to a central filing system if additional searches are unlikely to produce any marginal return; in other words, the agency generally need not search every record system") (internal citation omitted).
Thus, based upon the searches Bordley describes in his initial and supplemental declarations, the court concludes that the defendant performed an adequate search for responsive records.
For the foregoing reasons, the court grants the defendant's renewed motion for summary judgment. An Order consistent with this Memorandum Opinion is separately and contemporaneously issued this 19th day of May, 2010.
Our website includes the main text of the court's opinion but does not include the
docket number, case citation or footnotes. Upon purchase, docket numbers and/or
citations allow you to research a case further or to use a case in a legal proceeding.
Footnotes (if any) include details of the court's decision.
Official citation and/or docket number and footnotes (if any) for this case available with purchase.
Learn more about what you receive with purchase of this case.
LRC, Inc. About Us


text:
Roche Holding AG (OTCQX:RHHBY) Q1 2010 Earnings Call Transcript April 15, 2010 8:00 AM ET
Severin Schwan – CEO
Pascal Soriot – COO, Pharmaceuticals
Daniel O'Day – COO, Diagnostics
Erich Hunziker – CFO and IT Officer
Karl Mahler – Head, IR
Timothy Anderson – Sanford Bernstein
Sachin Jain – Merrill Lynch
Luisa Hector – Credit Suisse
Michael Leuchten – Barclays Capital
Alexandra Hauber – J.P. Morgan
Steve Scala – Cowen and Company
Marcel Brand – Credit Agricole
Jeff Holford – Jefferies
Amit Roy – Citigroup
Vincent Meunier – Exane BNP Paribas
Good morning or good afternoon, depending where you're attending from. I'm Stephanie, the Chorus Call operator for this conference. Welcome to the Roche first quarter 2010 conference call and live webcast. Please note that for the duration of the presentation, all participants will be in listen-only mode and the conference is being recorded. (Operator Instructions)
This call must not be recorded for publication or broadcast. At this time, I would like to turn the conference over to Dr. Severin Schwan, Chief Executive Officer. Please go ahead, sir.
Severin Schwan
Good afternoon, ladies and gentlemen, and welcome to our quarter one sales call. With me are Erich Hunziker, our CFO; and Pascal Soriot; and Daniel O'Day for our Pharmaceuticals and Diagnostics businesses, as well as, key members of our finance teams.
Please turn to slide five, you can see that we've had a very good start into 2010 with a 9% growth in local currencies on a group level and both divisions ahead of their respective markets. You see pharmaceutical sales were 10% up, if we exclude Tamiflu with solid growth of 8% in local currencies.
As to the currencies, you can see on slide six that we had a 3% impact on the group level, almost entirely due to the weakening of the U.S. dollar in the respective reporting period. As you are well aware and as you can see on slide seven, our growth is very much driven by biologics and for this very reason, the regulations on biosimilars and because of the U.S. healthcare reform has been of utmost importance for us.
On slide eight, we have summarized the key results as far as Roche is concerned and you can see that the 12 years of data exclusivity has been confirmed and that as expected the regulatory partners for biosimilars require clinical trials.
In terms of the financial impact of the U.S. healthcare reform, we welcome that healthcare coverage is expanded and this will certainly have a positive effect on our business in the long-term. However, in the short-term we will see additional rebates for Medicaid and certain hospital settings, which will have an impact of about 200 million Swiss francs in 2010.
Today, of course is a sales call, but turning to slide nine, let me also take the opportunity of reminding you of our strong pipeline and the fact that we want to launch six new molecular entities over the next five years.
Following our discussions with the FDA, I'm very pleased that we now expect one of those NMEs, namely T-DM1 already to be filed this year based on strong phase II data. Based on the good start, we confirm our outlook for 2010.
And with this, I'd like to turn over to Pascal for Pharmaceuticals.
Pascal Soriot
Good afternoon, everybody. It's really a pleasure to share with you our pharma Q1 results. So turning to page 12, as you can see we experienced a growth rate of about 10% in local currency in totality across the globe.
Excluding Tamiflu, we have an 8% growth rate and very strong result in every region as you can see here. There are a number of factors that influence this 8% growth rate. I just want to today tell you that the inventory valuation was very limited, very limited effect there.
And I'm happy to report that the underlying growth rate that we experienced here is about 5% to 6% if you include the CellCept and 7% to 8% if you exclude the effect of CellCept. So very much in line with the guidance we gave you for the whole year, which is mid single-digit growth excluding Tamiflu. And as you can see at the bottom of the chart here, the effect that we saw in Q4 is very much washed out with very good results for Q1.
Now moving on to page 13, Japan, where we experienced a growth rate of about 2%, excluding Tamiflu in the first quarter, we of course faced, like all our peers with price decreases for many of our products. However, the good news here is that the price impacts for most of our product was very minimal. The only decrease of substance affected Herceptin and was actually linked, so to an increase in volume, negotiation of larger volume and associated re-pricing for Herceptin.
Moving to page 14, it's really pleasing today to report this growth rate of about 12% for our oncology franchise, because I know a number of people actually at the end of last year were worried that our oncology franchise was slowing down. We actually told you that we expected a rebound in Q1 and a good growth rate for the whole of 2010.
And as you can see here, what we told you last year, actually, well, in January based on last year results was confirmed in the first quarter. You see here good growth across the various geographies, importantly, 19% growth in the international region, which once more demonstrates that the emerging markets are able to sustain the pricing of our innovative drugs and can grow strongly in these countries.
Page 15, if you look at individual brands, Avastin, MabThera and Herceptin all grew very nicely. Avastin actually essentially driven by lung cancer in Japan and colorectal and breast cancer in Europe.
MabThera, we have very strong uptake in CLL and also continued growth in intercontinental [ph] share in the international region and we have future growth that will come later this year and next year in the maintenance setting in Europe and the rest of the world.
Herceptin, 11% growth rate, this is essentially driven by the emerging markets but also very good growth in Europe and in the U.S. The gastric indication around the world but also extension of use in small tumor size is certainly having an impact. And as you can see here, very pleasing results for Herceptin as well. Xeloda and Tarceva are also doing very well.
I wanted to say a couple of words on the potential we see for Herceptin in many of our other innovative drugs in China on page 16. And as you can see here, there's a number of regions in China where we have reimbursement or partial reimbursement for Herceptin and Rituxan.
So it is possible at prices that are similar to what we experienced in Europe and the U.S. to get reimbursement in China. We've shown you before the kind of sales growth that we can experience each time we have – we achieve reimbursement with Pegasys certainly than others. So we certainly expect strong growth for Herceptin, MabThera in the years to come in China.
Slide 17, as Severin told you a minute ago, in the following discussions we had with the FDA, we made the decision to file early for breast cancer with T-DM1 on the basis of our phase II data, which as you know, as we communicated to you before, we're very strong – we had very strong response rate in third line metastatic breast cancer patients. And so on the basis of these clinical results and after discussing with the FDA, we decided to file early. So we will be filing this year.
We'll also be filing for ovarian, Avastin, on the basis of the clinical results we shared with you a bit earlier and we'll be presenting at the ASCO in May. Speaking of the ASCO, if I move to page 18, I'd like to attract your attention to some of the highlights, some of the key presentations, for Avastin, Rituxan and Pertuzumab. Avastin, of course, the ovarian cancer results.
Also, the gastric cancer results even though we didn't need the primary end point. We look forward to sharing the totality of the results with you in the medical community, including the secondary end point analysis for gastric cancer.
We will also be presenting the PRIMA results, which are very, very strong for Rituxan and MabThera in maintenance setting. And the new adjuvant study called NEOSPHERE for Pertuzumab, which also is extremely exciting. So we really would like to invite you to look at those results at the occasion of the ASCO.
If I move to page 19, looking at the inflammation immunology franchise, we experienced a decline in the first quarter, compared to last year, essentially due to the declines from decline of CellCept. But if you exclude CellCept, the franchise grew by about 23%. Every product grew quite nicely there and by region, you can see in Europe and in international regions good growth.
I'm happy to report that Actemra is developing very well. We have strong growth in Japan and in Europe, if you look at page 20. We also have a very successful start in the United States. It's really too early to be able to judge, I must say, but the earlier results, the feedback we get from physicians and the early market research we have done to assess the perceptions of this drug by the medical community, those results are very, very encouraging.
We have a strong clinical program that is supporting Actemra moving forward in earlier rate. Also, we have a head-to-head study versus Humira and our subcutaneous program is well on track.
Moving to page 21 on taspoglutide, we'd like to remind you that we have a very broad TMF program supporting taspoglutide, taspoglutide will be presenting at the ADA in June. And all our studies made their primary end points so far. So we are very encouraged by those results.
Page 22, as you can see the virology franchise also doing very well. Pegasys is growing nicely, 15% growth in the first quarter. We saw a pretty strong growth for Tamiflu and we re-forecast the same as we communicated to you earlier for the full year.
On page 23, some of the highlights for quarter one. And as you can see here, quarter one was very rich in news and most of those news were actually very good news. We got six major approvals, Actemra in the United States, CLL in the United States for Rituxan, Avastin in China for colorectal cancer, Xeloda in Europe in the XELOX regimen and finally gastric cancer for Herceptin in Europe. So, strong quarter from the point of view of approvals.
We had five – four major filings, in fact I should say five. You have the four that are listed here, but we also have Xeloda in adjuvant breast cancer. Actemra, as you can see here, the LITHE study in RA was filed. We filed in Japan for Herceptin in gastric cancer in combination with Xeloda and also filing for maintenance treatment for Rituxan/MabThera in the U.S. and the EU. We initiated two major phase III studies with Aleglitazar and our BRAF inhibitor for metastatic melanoma.
And finally, we had three phase III studies with that. The first one in ovarian cancer, I think this one is really of special significance, not only because the study was positive and met its endpoint, but also because if you look at the studies had two arms, a shorter duration of treatment for Avastin and longer treatment duration was 15 months. And the 15-month arm is the one that showed superior and met its endpoint and this will have significance for treatment duration and we find those results very encouraging.
Of course, when you pursue innovation, you cannot succeed constantly, so we experienced less positive news with gastric and prostate with Avastin and those studies didn't meet their primary endpoint. But as I said a bit earlier, we look forward to sharing the totality of the data at the ASCO in particular the secondary endpoint.
Finally on page 24, we'd like to remind you of some of our key objectives for 2010. We have a major news flow, as you can see here with Avastin, ocrelizumab and many of our products. And in terms of filings, we have several filings, two of those we have already achieved MabThera in maintenance and Xeloda in adjuvant breast cancer. Just like to make two comments here.
One is Avastin gastric cancer is still listed because we haven't made a decision as to what we will do as far as filing in that indication. And Ocrelizumab RA is also there even though we suspended dosing patients in our ongoing program. We are analyzing the data before we made a decision as to the future of the RA program.
Thank you very much and I will hand out to Daniel.
Daniel O'Day
So, good morning, good afternoon everybody. It's – I would like to start on slide 26 by presenting the first quarter sales results for the Diagnostics Division. And the overall message here is that we continue to strengthen our world leading position in in-vitro diagnostics by growing significantly above the marketplace.
You can see in all of the business areas contributing to that growth. And in particular, the highest absolute contributors to growth in Professional Diagnostics in diabetes care and in our Applied Science division with the local growth rate of 9% overall for the division.
Now, if you turn to slide 27, it gives you a little more color into what's driving this business. And just as a reminder, the major source of competitive advantage for us in this business is the large installed base that we have as a market leader throughout the world. And you can see in each one of our businesses we have advanced in that regard. So on Professional Diagnostics, our clinical chemistry immunoassay business, we have strong placements in the cobas 6000 and 8000 and the introduction of three new assays on that platform throughout the world.
In Diabetes Care, we continued to expand our meter placement particularly ex-U.S. with those same innovative products lining up for filing and approval in the United States. Molecular Diagnostics has good underlying demand. There's some quarter-on-quarter effect there. But we continue to have good growth in our blood screening business in particular in the first quarter. And also strong rollout of the cobas 4800 system, which is our HPV and CT/NG system and we reiterate our intention to file in the United States for HPV with the ATHENA trial in the second quarter of this year.
In Applied Science, we had very strong growth that was driven predominantly by our PCR research use systems and array business and also significant growth in Asia Pacific and in particular in China with the placement of many of our systems.
Tissue Diagnostics continues the strategy of growth both in the United States in the advanced staining business and even higher growth ex-U.S. for the penetration of our tissue diagnostics, Ventana line into that marketplace.
Now as you move to slide 28, what I would like to do is just give you two examples of the instrument base that is driving the vast majority of the growth in the first quarter. I will start off with our Professional Diagnostics business. And here just to remind you, we began the introduction of our cobas 8000 system in this business, which is the system for very high throughput labs last year. But this is a modular system that we introduced over the course of multiple years.
And the C here refers to clinical chemistry whereas the E refers to the immunoassay modules. Particularly in the immunoassay business, we are enjoying a 15% growth this year in the first quarter. And as you can see here, we are preparing to launch the immunoassay module in the second half of this year that will connect with the clinical chemistry modules that we launched at the end of last year and the beginning of this year.
Moving to slide 29, you can see the Diabetes Care business continuing to launch innovative new products in the marketplace. The vast majority of the growth in the first quarter is driven by our Aviva Nano and our Performa Nano business. At the same time, we introduced at the end of last year and continuing into this year, two new meters that make significant advances in diabetes. One is a strip-free meter system for the Accu-Chek Mobile. And the other one is an integrated system that integrates our pump device and blood glucose monitoring in the Accu-Chek Combo. And these are being launched in many markets at Europe and in APAC.
Now if you move to slide 30, transitioning from the combo system, we announced this past Tuesday to full acquisition of Medingo, which is a patch pump technology. And this is an excellent complement to our durable pump business, but it allows for significant advantages. Just to give you an idea of the size of this market, the blood glucose market is around $9.5 billion. The insulin delivery market is about $1.6 billion and a high growth business at 11%.
And within this segment, although newly launched we see an over-proportional growth in the patch pump segment. Particularly in those that are new to the pump business. Now the hurdles that we have with the current durable pump business in the marketplace deal with the weight, size and the infusion set of the business as well as the high upfront costs.
The advantages of the Medingo Technology which will add to our Diabetes Care portfolio are that it is very small, lightweight, (inaudible) and it allows for greater patient convenience and also significant lower upfront cost for the patient.
This product is 5, 10-K approved in the United States. It was filed for approval in Europe and our key task now is to take this from a manual production process to a scale-up process for anticipated launch in 2012.
Finally, on slide 31, just to report on the scorecard for the division, we continue to roll out the products as committed to you at the end of last year with the green checkmarks. We reiterate our guidance for the year, which is to grow significantly above the market.
And I would just point your attention to the next diagnostic investor event, which will occur in conjunction with the AACC on July 26. Thank you for your attention. I turn it over to Erich Hunziker now for the financials.
Erich Hunziker
Thanks, Dan. Good morning, good afternoon, ladies and gentlemen. If we move to slide 33, I wanted to give you a very quick hint at the currency impact and you have much more detail on the charts 120 to 126. But maybe counterintuitive reading everyday about Greece and the problems of the euro, the good news for us is that the major impact in the first quarter originated actually by the U.S. dollar and the euro had a very minor impact on sales.
I know this is a sales call only, but most of you are very familiar that also our bottom line is mainly sensitive to the euro developments. So the first quarter definitely is nothing to worry about from this angle.
And if we go to chart 34, I can really report that we are even ahead of our scheduling debt repayment in a sense. We always said by the end of 2010 we wanted to have 25% of our debt paid down. The fact is actually that by today, we already have paid down 27% of the debt and our liquidity is absolutely in great shape even after serving all the bonds in March and paying out this very attractive dividend to all our shareholders. So this confirms that the maturity profile we had issued last year was totally in line with our business perspective and we are on a good track to pay down.
And this actually finished the presentation. You may have realized we wanted really to make room for as many questions as possible for you, to listen to you and to serve you as good as possible. So if we may have the first question, please?
Question-and-Answer Session
(Operator Instructions). The first question is from Mr. Timothy Anderson, Sanford Bernstein. Please go ahead, sir.
Timothy Anderson – Sanford Bernstein
Thank you. A few questions. On Avastin in breast cancer, in your mention of converting the accelerated approval in breast to full approval, do you expect that there will be an FDA advisory committee for this? Also on Avastin, do you expect that we will see any data from the Hellenic Oncology group trial, looking at six months versus 12 months Herceptin duration in early breast cancer at ASCO?
And last question on your CETP and inhibitor, you mentioned an interim analysis being done on that outcomes trial in 2011. From what I understand interim analyses aren't done very often in big cardiovascular outcomes trials. So I'm hoping you can give us a little bit more information here. Should we presume it's being done 150% of total events are reached? And does it embed a futility analysis and presumably this is an efficacy look?
Severin Schwan
Pascal Soriot
Okay. So, to address your first question. The breast cancer approval in the United States, it is difficult to say what the FDA will decide to do, of course, but we – I think it is reasonable to expect that there will be a no (inaudible) indeed. So that's our expectation but we can't be sure. We believe that on the basis of the data we presented, we should get approval for Avastin breast cancer. And so we look forward to the discussions with the FDA.
Second question was assessing six months versus 12 months. We don't expect any new data to be presented there at the ASCO. We have as you know, we have our own HER2 study running that we expect to show to demonstrate the 24 month statement will be spread to 12 months. But for this year I don't expect new data.
And the final question regarding the six [ph] interim analysis in 2011, that interim analysis was built in the protocol from the beginning. And we don't – the study will have to meet a certain threshold of overwhelming efficacy. So if we show the very strong efficacy then we could actually stop the study and then meet indeed a stretch NDA filing of 2012 or something like this. But of course, we will have to meet this criteria, the stopping criteria of superior efficacy.
Timothy Anderson – Sanford Bernstein
And I'm sorry. Just on dalcetrapib again, is there a futility analysis built into that? And is that being done once 50% of total events are being reached?
Pascal Soriot
There is also – yes, there is a future analysis that is built in that will be right at the end of this year actually but it's a safety analysis. And we don't expect that we will be filing on the basis – on the back of this analysis. It's just assessing the safety of the drug. The only time point – early time point that could lead to an early filing, if that's behind your question is the interim analysis of August or so 2011. And that one is an efficacy-driven analysis.
Timothy Anderson – Sanford Bernstein
Okay. Thank you.
Severin Schwan
You're welcome. Can we have the next the question, please?
Next question from Mr. Sachin Jain, Merrill Lynch. Please go ahead, sir.
Sachin Jain – Merrill Lynch
Hi. Thanks for taking my questions. Three important questions again, please. Firstly on T-DM1 with the earlier filing confirmed, wondered whether you could just revisit your thoughts on potential for premium pricing relative to Herceptin in the first indication, particularly when you think about future indications, whether cost per quality data may be stronger.
Secondly, again on Avastin breast cancer, just any thoughts on whether the Virgo Registry data is available at ASCO and whether you would have plan to use that data as part of any advisory committee meeting.
And then finally on taspoglutide, any color on whether the FDA has signed off as yet on your ability to use events from the original emerge studies as part of the safety filing, including data from T-emerge 8? Thank you.
Pascal Soriot
So Sachin, thanks very much for the question. T-DM1 premium pricing, you cannot answer this today. We are working on it. Certainly, this product can sustain premium pricing. There's no doubt in our mind. The question is what kind of pricing can it sustain in comparison to Herceptin. We are actually working on this and modeling the health economics of this drug and based on the expected clinical benefits.
We're also doing payor research both in the United States and Europe right now. So it's a little bit early to say what kind of pricing we would be able to sustain. In breast cancer, Avastin the registry, I have to say I don't know. We will have to get back to you on this one.
Severin Schwan
I don't know. And I need to check.
Pascal Soriot
Yeah. And the taspo question, the answer is we don't know yet.
Sachin Jain – Merrill Lynch
Thank you very much.
Severin Schwan
You're welcome, Sachin. Next question please?
Next question from Ms. Luisa Hector, Credit Suisse. Please go ahead, ma'am.
Luisa Hector – Credit Suisse
Good afternoon. I have three questions. On Herceptin, can you tell us what proportion of sales perhaps are coming from gastric? Do you feel that gastric was contributing to Herceptin in the first quarter of 2010? And on Rituxan, I think you are saying that the RA indication is still growing. Is it fair to assume it's growing in both the U.S. and ex-U.S.?
And could you perhaps talk about the positioning of Rituxan and Actemra together and maybe a bit more color on the Actemra launch in that regard? And then finally, on the health-care reform, just to clarify, the Medicaid rebate that's backdated to the 1 January, that is fully booked into Q1 sales?
Pascal Soriot
So the first question, thanks very much. The first question, Herceptin gastric, it is a little bit difficult to assess the impact of gastric cancer because we don't yet have in Europe. And we don't yet have the research that we have run on a quality basis. It is reasonable to expect a small impact, but not a big impact yet because reimbursement – we don't have reimbursement; we don't have approval in a number of markets. In the U.S. our assessment is that the impact of gastric cancer is still very limited. There must be some off-label use, certainly, but it is relatively limited for the time being.
The growth you see for Herceptin is actually in the quarter one, is actually more influenced by the fact that in a number of regions in Europe, but also the United States, we have now been able to add the small tumor size, those small tumors that are less than a centimeter in size in the guideline. So they are in the NCCN Guidelines in the U.S. They are in the national guidelines in Europe. And this is certainly having an impact on our growth rate. You also see the impact of the growth in emerging countries from stem cell in Brazil. We are getting access to the public market. All of this is actually driving sales in quarter one. Gastric has a small impact, not much. I think gastric will be driving our growth moving forward for the rest of the year.
The second question related to Rituxan RA. In the U.S. we don't see a lot of growth in rheumatoid arthritis with Rituxan. A little bit, not much we see growth outside the U.S. in RA. And in the United States, the focus right now is very much on Actemra. Of course, to address your question, Actemra is – in their own run, the positioning for Actemra is really the first-line biology agent. And in fact, we are doing – we are hoping that we will position it as a first-line agent for RA in the long run, but certainly first line biology in the midterm. And MabThera/Rituxan because of its profile will probably be more an agent to be used for TNF failure or first-line biologic failure. So you can imagine Actemra being used first and Rituxan second.
And there is room for both products because patients unfortunately will evolve and their disease will keep progressing. And this is a very broad market with a lot of patients, a very large market, lots of anti-TNF, so there's room for the two products. And the last question regarding healthcare reform, the answer is yes. We have $37 million accounted for in terms of Medicaid rebates in the first quarter.
Luisa Hector – Credit Suisse
Thank you.
Severin Schwan
Can we have the next question, please?
Next question from Michael Leuchten, Barclays Capital. Please go ahead, sir.
Michael Leuchten – Barclays Capital
Thanks for taking my question. One follow-on question on the healthcare reform, not on the U.S. side but on the European side. We've seen quite a few countries now making comments about pricing levels and healthcare reform going forward. How do you budget for that internally at the moment? How do you think about that?
And then another question on the international markets, since you flagged that, looking at your disclosure since the beginning of 2009, the growth rate, excluding Tamiflu and constant exchange rate is somewhere between 7% and 16%, quite a wide range. Do you have a feel for what the underlying sustainable growth rate is in that part of your business?
Severin Schwan
This is Severin. If I can take the first question on the health-care reforms outside of the U.S, I mean, continued price pressure is not new. We see this continuing in Europe. We have, as you know the usual biannual price decrease in Japan. I would say the one event which stands out is the first announcement of the German government on German healthcare reform. At this point of time, it is really too early to say what the exact impact will be.
We, at any rate, stick to our guidance for the rest of this year. But it is still in a draft status. We are at the status where we have been in the U.S. sometime ago. So it is too early to say how this will actually play out, for the international markets, Pascal?
Pascal Soriot
Yes. For the international markets, it varies according to regions because the international region is of course made of very different markets that are growing at different rates based on their own economies. And of course, as you know, China is not only leading the pack in terms of overall growth from an economic, but also from a pharmaceutical market viewpoint.
In the first quarter, the number, the growth rate you saw here for the international region is influenced by tenders and the timing of those tenders. And especially in Russia, we had tenders coming in the first quarter that came in the first quarter of this year, not last year. In fact, the year before, they came in the last quarter. So that influences the overall growth rate. I would say the underlying growth rate across the international region is probably around 10% with a higher growth rate for Asia.
Michael Larvden – Barclays Capital
Thank you.
Severin Schwan
Can we have the next question, please?
Next question from Mrs. Alexandra Hauber, J.P. Morgan.
Alexandra Hauber – J.P. Morgan
Thank you. Good morning. I have two questions. Firstly, on Herceptin, I was surprised this morning in the presentation when I saw that 18% Japanese price cut. But you refer to some volume contracts and I was just wondering whether you could give us anymore color on this, how exactly that trade-off happens.
And the second question is just, is actually to Erich. You mentioned that the 5billion debt pay-down in the first quarter and obviously you've also paid the dividend, but you probably didn't quite have 10billion free cash flow in the first quarter. So I was wondering whether you could give us any idea what net debt figures actually are at the moment.
Erich Hunziker
Okay. Actually, it will not surprise you. It went slightly up because the first quarter is definitely the most cash out quarter. It will not surprise you all our bonds are served on an annual basis, their interest rates. And we repaid, as you have seen in my chart, we repaid a dollar bond and we repaid also some one-year notes. And therefore and the dividend was paid out. So it will not surprise you that our net debt situation has worsened by the end of the first quarter. But as I said, I am absolutely not worried by this seasonality of liquidity. Our liquidity position is absolutely strong at the moment.
Alexandra Hauber – J.P. Morgan
But that change in the net debt is – you haven't really just replaced the bond with tapping in the commercial paper market. You really have tapped into your marketable securities, I would assume. So we should still see the benefit on the financial bottom line?
Erich Hunziker
Pascal Soriot
The other question Alexandra, relates to Herceptin in Japan. And in Japan, you tend to negotiate. Often you negotiate price, it's a little bit like to do in France on the basis of a kind of a price volume agreement with the payer. And because the product has been very successful in Japan in adjuvant and metastatic breast cancer, we exceeded the budget that had been originally negotiated with the government. And therefore, we got us a higher than expected price decrease to compensate for the higher than expected volume growth that we experienced.
Alexandra Hauber – J.P. Morgan
Okay. Is there another big threshold when there is the next big price cut coming? Or was that just an initial one?
Erich Hunziker
Sorry. I'm not sure I heard the question. There was some noise on the line. Did you ask me if we (inaudible).
Alexandra Hauber – J.P. Morgan
Yeah. But it looks to me what you're saying is that this for the volume, that is already achieved rather than for an anticipated volume growth in the future. So I was just wondering whether there's another threshold, if you reach that one, whether there is another sort of major price cut which would be out of the ordinary in about two years time?
Erich Hunziker
To be honest, I don't know precisely. I would have to get back to you on this one, but I would assume the answer probably is there would be no major impact. But we will check and get back to you on it.
Alexandra Hauber – J.P. Morgan
Thank you.
Severin Schwan
Can we have the next question, please?
Next question from Mr. Steve Scala, Cowen and Company. Please go ahead.
Steve Scala – Cowen and Company
Thank you. I have four brief questions. First, it was stated that the inventory impact was very limited in the first quarter, but can you tell us whether it was a positive or a negative impact? Secondly, what were Actemra U.S. sales? Third, what were the issues with Ocrelizumab in RA, which are causing you to rethink it? And then lastly, what is the status of the AVANT study and when would you expect a read out? Thank you.
Pascal Soriot
So the inventory impact, the inventory impact was I don't know – positive or negative. Depends how you look at it. Let's say that the – there was a slight increase in channel inventory that led to a small impact of 1% on the growth rate. We will always experience variations from one quarter to another in terms of the level of inventory that exists in the channel. So, it's never going to be completely zero. But certainly 1% is at the level that you could consider, that you could ignore. So it's very small.
Second question was Actemra. Sales in the U.S. were, for the quarter 5 million. As I said, it is too early really to judge the sales per se. We started really launching in February fully. The only thing we know so far is the feedback from market research and from physicians is very good. As you realize in the U.S, you of course have to gain reimbursement from each individual commercial payer. And as far as Medicare, you get a theoretical measured reimbursement except that you get a temporary code which typically in the first few months doesn't really work so well. And physicians are never sure patients will be reimbursed, so they're very cautious. So right now, we're working through all those normal issues to gain full reimbursement. And then the sales should accelerate from Q2 onwards.
Thirdly, Ocrelizumab RA, we experienced an imbalance in infections in the Ocrelizumab arm, especially in coming out of Asia. We are right now analyzing the data to understand what they mean, whether we have differences between low dose, high dose, it is too early to judge, so. But the IDMC recommended that we should stop dosing patients out of being cautious here. The AVANT study, right now we are expecting it to read out by the end of this year. It is event-driven as you know, so it could vary, but right now our best guess is end of this year.
Steve Scala – Cowen and Company
Thank you.
Severin Schwan
You're welcome. Can we have the next question, please?
Next question from Mr. Marcel Brand [ph], Credit Agricole. Please go ahead.
Marcel Brand – Credit Agricole
Thanks for taking my question. You said pricing overall had a limited impact in the quarter. Could you give us maybe a number of what the overall pricing impact in pharma was? Then on Ocrelizumab, why does it take so long for the Phase II data to be presented in detail? Obviously the American Academy, it didn't come? And yes, that's already it.
Pascal Soriot
Well, Ocrelizumab MS is, it's not taking long. It's just that we made the decision to present those data at a Congress. And so, there's nothing really special related to this. It's a decision we've made from the point of view of communication of the data to the medical community. We want to make sure those are presented to a Congress where they can be recognized by the experts who come.
Pricing, I can't tell you the precise number. We'll have to get back to you on this, but I would expect it's relatively low. You have to keep in mind, as we have mentioned before, first of all, outside the U.S. there is never any price increase. So rarely, in fact, typically a price decrease is whether excess or appeals in Japan, you have price decreases. And around the world you tend to have price decreases for us and everybody else in the industry. Where we are with threshold is that many of our peers are able to increase price in the U.S. by 10%, sometimes more. And of course, your question becomes very relevant for those.
In our case, because of the niche of our portfolio, we don't increase price much at all. So in the United States, the price effect typically would be – sorry – 2% or 3% per year, so you take 2% or 3% in the United States and a zero or negative impact from the rest of the world. So that gives you an idea that the total price increase effect which we could give to you separately is in any case relatively marginal.
Marcel Brand – Credit Agricole
Severin Schwan
You are welcome. Can we have the next question, please?
The next question is from Jeff Holford, Jefferies.
Jeff Holford – Jefferies
Hi. I have got three questions, please. The first is on CellCept. I wonder, if just in the U.S., ex-U.S., you can just give us the current split on also – give an indication in transplant as far as you can measure that. Secondly, I wonder if you can at all quantify the level of destocking that you did have in Japan in the first quarter of this year. And just lastly, on AVANT, are there any subgroups in that study that you are now prospectively looking at, given some of the more sustained benefits you saw in some subgroups in the CO8 study and could you potentially have regulatory discussions on the back of some of the subgroups that were seen in both the CO8 and AVANT studies? Thanks.
Pascal Soriot
So the second question actually is Japan. We had a small impact but very small in fact, the price decreases we experienced in Japan this year were relatively limited except for Herceptin. Herceptin had a substantial price decrease for the reasons we discussed. Many of our other products didn't experience big price decreases at all, actually and so the destocking effect in the first quarter at the wholesaler level and hospital level was very limited. So I will not say – I could not say we had a big effect there. In terms of the AVANT study in the subgroup, I can't answer that question right now. I don't think we have any specific subgroup analysis planned for. It doesn't mean that when the study read out, we could not go back and retrospectively do some further analysis of subgroups, but there is no pre-planned analysis of various subgroups.
And finally, your last question I think related to CellCept. And I guess your question relates to CellCept in the U.S. versus the rest of the world, so if I give you the data for Q1 2010, because it's probably the more up-to-date data, the U.S. now represents about 20-something-percent of the total global sales. So it's relatively on a quality basis, so it's relatively limited. We have certainly declined and a bit more than 20% of our robust sales come out of the U.S. now.
Jeff Holford – Jefferies
Sorry. I was just wondering if you can break out the sales between some of the indications that they use whether it is – and what the mix is in transplant and autoimmune disease, if possible?
Pascal Soriot
Well, in the United States, essentially you could assume what's left is really transplantation. Most of the immune use of the drug has been lost to generics and it was lost to generics very rapidly. In fact, we have been able to stabilize – not stabilize but almost stabilize the sales, decline is very, very slow now in terms of our total share with CellCept and we have been able to stabilize it functionally, thanks to the transplantation part of the franchise.
Jeff Holford – Jefferies
Can you just remind us of the mix outside of the U.S., please?
Pascal Soriot
Excuse me?
Jeff Holford – Jefferies
Can you just remind us of the mix of the transplants also outside of the U.S. as well, please?
Pascal Soriot
This I can't tell you from – what I know is that it varies substantially from country to country but I could not tell you from memory. I think it is very limited outside the U.S. because essentially we don't have reimbursement and in most countries outside the United States, at least in Europe, if you don't have reimbursement, you don't get off-label use and physicians really stick to that. So I think it's very limited but I can't tell you the exact number offhand.
Jeff Holford – Jefferies
That's great. Thank you.
Severin Schwan
You are welcome. Can we have the next question please?
Next question from Mr. Amit Roy, Nomura. Please go ahead sir.
Amit Roy – Citigroup
How are you? I'm not working at Nomura. Just a couple of questions, firstly on Avastin, you presented a full overall survival data of the AVADO study in San Antonio. And at the same time, the abstract book's data, the RIBBON-1 data in full was just represented in San Antonio, but for some reason wasn't. I'm surprised to see that we don't see the full overall survival data driven more at ASCO, especially considering the interim Helpid [ph] ratio is greater than one on death. So when were we getting interim 1 at ASCO this year or when will we be getting that data, especially considering the approval process for the FDA?
And secondly, on taspoglutide, are you looking at any way of reducing the vomiting rate, the nausea and vomiting rate that is associated with taspoglutide at higher doses? I guess my question is if you had to go to a 10 milligram dose to be equivalent to Lantus, are there any ways you can then deal with this vomiting rate – vomiting and nausea rate that one is experiencing?
And lastly, just more of a philosophical question on Herceptin, do you see any potential from not generics, but actually genuine biosimilars of Herceptin, such that a competitor company essentially takes the HER2 antibody, develops it themselves formerly in Phase III clinical trials and launches it as a separate branded drug. Do you see that potential existing for Herceptin in the future? Many thanks.
Karl Mahler
Yeah. Amit, Karl speaking here. For the update or survival, we usually present the data and they are mature but let me check when we are going to present it to them. If we have it for you, as we always do, we share it with the public. There is no problem with that. For the rest of, Pascal, if you…
Pascal Soriot
I'll take the easier one. taspoglutide, yes, we are looking at how we can manage the Novie Arvo [ph] meeting. And essentially, you have two avenues we can explore. One is titration, start with lower dose and titrate up and certainly we will be looking at this. And the second option is time of registration. If you give the drug in the morning, it is logical to assume that you may have more nausea in the morning that you will have it if you give it at night with a full meal.
So we are looking at time of administration of drug. So we're going to look at both of those to see whether we can manage the Norvie Arvo [ph] meeting as we move forward. And Herceptin, I hope I captured your question precisely. In the United States, of course, we are not talking about biosimilars for a long time and just for memory, the healthcare legislation states that a biosimilar would have to show similarity, which has to be now defined by the FDA. The similarity is understood today as demonstrated by head-to-head study of a biosimilar versus Herceptin, demonstrating similar efficacy, non-inferiority efficacy. So that is very important because it may mean very large studies. On top of this, to be fully reimbursed, approved and reimbursed, for not only new patients, but also patients on Herceptin, the biosimilar would have to demonstrate intangibility. So they would have to demonstrate that you can switch from Herceptin to biosimilar, back to Herceptin, back to a biosimilar, which is what physicians will do in practice without impacting efficacy. So, you can see in the U.S., the weather [ph] is pretty high.
In Europe, it is of course possible to imagine a biosimilar in a number of companies, as you probably know, will be working on – some of them working on that. I think what is important to remember is that every biosimilar is going to be made out of a cell line that is not our cell line. So essentially even if you develop the same – a drug that looks the same, it is not necessarily the same biologically because it hasn't been made with the same cell line. And we will be working, we are working – we will be working with the authorities to share our point of view in terms of the science that surrounds those biosimilars. But, of course, we can imagine that they may be able to make it to the market at some point in time.
Amit Roy – Citigroup
Just on my question, rather than the biosimilar what I meant was essentially a competitive firm making their own HER2 antibody, doing a full development package and just doing a Phase III clinical trial in say first-line metastatic breast and so you end up with a different drug but essentially a competitor in the HER2 space is probably similar especially with a head-to-head study. And since that would be a pretty easy win for one of the large U.S. competitors to do, who got large sales forces not selling very much at the moment, rather than a biosimilar per se. And just another point of clarification, have you submitted the full overall survival data to the FDA in your regional submission back in November for RIBBON-1?
Pascal Soriot
So, I mean, the first question is anybody can of course at any point in time develop a new monoclonal antibody that has efficacy in breast cancer that will be competing with Herceptin. But to do this, you have to develop it completely as you just mentioned yourself; it would take years.
Severin Schwan
And as long as it doesn't interfere with our patent.
Pascal Soriot
And as long as it doesn't interfere with our patent, for sure. So if it doesn't interfere with our patent and they develop it fully, yes, they could get there. But they would get there after – if they started now, they would get there after we've lost patent. So, I'm really not sure practically who would want to do that, actually.
Karl Mahler
Yes. And for the finding, we always update the filing continuously, so whenever we have new data, we usually file it. I really need to check what was filed at the time and if there is an update to be done, honestly I don't know. But if you could give me a call later on, I could get back to you and share with you whatever we have filed or not. We think that we have a very compelling – in order to get full approval in the United States, just to conclude or to summarize our position.
Amit Roy – Citigroup
Many thanks, Karl.
Severin Schwan
You are welcome. Can we have the next question, please?
Next question from Mr. Vincent Meunier, Exane BNP Paribas. Please go ahead sir.
Vincent Meunier – Exane BNP Paribas
Hello. Thank you for taking my questions. The first one is on Avastin in China. Can you please give us guidance on the timings for the reimbursement discussions with the health authorities there and also, any color regarding the size of the targeted population there. And also, what are the potential indications outside colorectal cancer, maybe in lung cancer, for example? The second question on taspoglutide, that's a follow-up question, just to understand well. Do you have the possibility to file early 2011 on the back of the interim results of the cardiovascular study or do you have to wait for the full cardiovascular results?
Pascal Soriot
Well, for the Avastin China, just from memory, we have approval for colorectal cancer at this point in time. Essentially, we will be marketing Avastin in China like we have been marketing our other drug Herceptin and MabThera [ph] for a long time, i.e. in the so-called out-of-pocket or private market. So those are patients who pay themselves or alternatively have private insurance. There's a growing population in China especially in the large cities, people working for companies that provide health insurance and so those are the people we would be marketing the drug to.
In terms of getting reimbursement at the level of provinces, it is going to take quite a long time, as we have experienced with Herceptin and MabThera, so it's a progressive effort. We're making good progress with Herceptin and MabThera but Avastin, you shouldn't expect it will impact us in the very near term. The other indications are that we are working at – looking at our lung cancer of course and breast cancer. And also, we'll be looking at gastric cancer. So we need to do local studies and so we are in the process of working on those indications. But the biggest potential is colorectal and lung in China. As far as – then you had another question which was taspo. The T-emerge 8, just from memory, this is a cardiovascular safety study and so we basically expect that it will read out next year and enable us to file in 2011 and we don't expect that we will be able to file earlier than that.
Vincent Meunier – Exane BNP Paribas
Did you consider that you can file an interim results from the T-emerge 8 trial or do you think that you will need the complete results of T-emerge 8?
Pascal Soriot
It's a question of events. It's a question of a number of events. Essentially, we have calculated the sample size and based on the event rate that we will expect in this population so that we will file as soon as we have a risk ratio of less than 1.8 as the FDA guidelines indicate and then the full study will be filed later on. But there is – in our plan today, we will file as soon as we reached enough events to demonstrate the risk level less than 1.8 and that would be in 2011. So we are doing it as fast as we can. There is no way that we could file earlier than that.
Vincent Meunier – Exane BNP Paribas
Thank you.
Severin Schwan
You are welcome and this leads us with time for one more last question, please.
We have a follow-up question from Mr. Marcel Brand, Credit Agricole. Please go ahead.
Marcel Brand – Credit Agricole
Sorry to follow up on the previous question. I didn't understand the answer well. There is or there is not, in your expectation, an FDA advisory committee meeting on Avastin in breast cancer?
Pascal Soriot
Well, the answer is actually we don't know. It's probably why you didn't get the responses. In fact, we don't know and we can't decide for the – at the end. They haven't told us what they will do. We can only speculate and in the context of speculating, it will be reasonable to expect that they might call (inaudible) because of course this is a very important decision to make, not only for Avastin in breast cancer, but also as a precedence for future products. What is the – what is the value of PFS? When and how do they accept PFS as an endpoint versus overall survival? They really have to kind of establish some more moving forward. So it will be reasonable to expect they might call and know that but we can't decide for them and they haven't told us anything.
Marcel Brand – Credit Agricole
Thanks very much.
Severin Schwan
You're welcome. And this brings us to the end. Ladies and gentlemen, thanks a lot for your continued interest in Roche and looking forward to a continued attractive year for Roche and all the contacts with you in the future. Thank you.
Ladies and gentlemen, the conference is now over. Thank you for choosing the Chorus Call facility and thank you for participating in the conference. You may now disconnect your lines. Good bye.
Copyright policy: All transcripts on this site are the copyright of Seeking Alpha. However, we view them as an important resource for bloggers and journalists, and are excited to contribute to the democratization of financial information on the Internet. (Until now investors have had to pay thousands of dollars in subscription fees for transcripts.) So our reproduction policy is as follows: You may quote up to 400 words of any transcript on the condition that you attribute the transcript to Seeking Alpha and either link to the original transcript or to www.SeekingAlpha.com. All other use is prohibited.
If you have any additional questions about our online transcripts, please contact us at: firstname.lastname@example.com. Thank you!


text:
Back to top
Select Language
Chinese (Simplified)
Send Inquiry
Home Page
Company Profile
Our Products
Vegetable Crate
Material Handling Crates
Packing Crates
Plastic Crates
Storage Crates
PP Corrugated Crates
Multi Purpose Crates
Insulated Water Jug
Insulated Hot Water Jug
Insulated Plastic Water Jugs
Insulated Water Jug
Thermoware Water Jugs
Household Water Jugs
Plastic Water Jug
Colored Plastic Water Jugs
Insulated Thermo Water Jug
Water Dispenser
Plastic Water Dispenser
Drinking Water Dispenser
Contact Us
Offering premium quality and Insulated Water Jug,
Plastic Vegetable Crates & 20 Ltr Pet Bottle,
at competitive price rates.
About Our Company
Climbing the ladder of success since the year 2011, we,
Iskcon Plast
, are pleased to introduce ourselves as a prominent
Manufacturer, Supplier, Wholesaler and Distributor
. We deal in a wide assortment of
Plastic Products
that have found a good place for themselves in the market. The array consists of
Insulated Water Jugs, Plastic Vegetable Crates and 20 Ltr Pet Bottle
As we use biodegradable and environment friendly plastic in the manufacturing of these products all our customers and buyers choose our products over the rest manufacturers. Our products have always matched with the set quality standards and will continue to do so due to our good manufacturing and total quality management policies. Other than this, we have a huge production line as well due to which we are always able to meet with the rising market demands as well.
Read More
Most Popular Products
Drinking Water Dispenser
Click here
Insulated Hot Water Jug
Click here
Packing Crates
Click here
Plastic Water Dispenser
Click here
Insulated Thermo Water Jug
Click here
Storage Crates
Click here
Best Seller
Insulated Plastic Water Jugs
Click here
Thermoware Water Jugs
Click here
Multi Purpose Crates
Click here
Latest Trade Offers
Water Jug
Being a highly considered company, we are engaged as manufacturer and supplier of Water Jug in Rajkot, Gujarat, India. We provide drinking water jug, ..
Water Jug
We are manufacturer of Water jug, Drinking water jug, insulated water jug for our client. Features : Durable construction Elegant design Contemp..
Our Infrastructure Plant
To meet with the huge requirements of the plastic industry is amongst the top-most priorities of our organization. And, in order to be successful in this we have backed ourselves with proper sound infrastructure facilities at our industrial premises in Rajkot. The manufacturing, quality inspection, packaging as well the storing departments all are well equipped with robust tools and technologies with the use of which our team performs their respective job within the scheduled time-frame.
Read More
Contact Us
Gondal Road, Near Gondal Road Circle, Back side of Maruti Perfect Showroom, Rajkot - 360004, Gujarat, India
Mr. Ishan Joshi (Partner)
Mobile :
+918866411011, +919879530087
Accepts only Domestic inquiries
Send Inquiry
Send Inquiry
Send SMS
Send Inquiry
ISKCON PLAST All Rights Reserved.


text:
Bus from Königsbrunn to Neuhofen and return
Find cheap coach tickets for your bus journey from Königsbrunn to Neuhofen and back
You want to travel for less? You're looking for a bus from Königsbrunn to Neuhofen? Have a look on our webpage, we'll help you catching the intercity bus route , which suits your preferences perfectly. Compare all the times, durations, routes, prices and comfort features on CheckMyBus and decide yourself, which bus provider you'll take. This bus route is currently offered by the bus provider FlixBus.
Find out more details about the service on your bus from Königsbrunn to Neuhofen and return
Coach connections
International coach connections


text:
Blueberry Mojito
Blueberry Mojito: Cool off this summer with sweet blueberries, tart limes, and a refreshing splash of rum. This cocktail will sweep you away like a cool island breeze & is perfect for lazy summer afternoons!
Blueberry Mojito Royale. Summer's new signature cocktail. #SummerSoirée #cocktail
This Blueberry Mojito Mocktail is a refreshing, summery drink that's perfect for baby showers or brunch!
Blueberry Mojito - 1 cup fresh blueberries (plus extra for garnish), 4 oz clear rum, 10 fresh mint leaves, 2 teaspoons sugar, juice of 2 limes, 6 oz club soda, ice
Black and Blueberry mocktail grape cherry or pomegranate juice honey
Blueberry mojitos - simple and delicious. Perfect summer cocktail. Take some intox-detox and prevent the negative after effects of alcohol and don't regret this delicious drink! @intoxdetoxid or www.intox-detox.com for free samples!!
A fruity, summer staple just got made over! Skinny Sparkling Blueberry Mojito is fruity, minty and super refreshing when made with a homemade blueberry simple syrup and topped with sparkling water!
Lavender Blueberry Mojito - For more delicious recipes and drinks, visit us here: www.tipsybartender.com
Mint & fruity, light & easy, this larger batch blueberry mojito recipe is the perfect cocktail for spring and summer entertaining. Vegan.
Blueberry Mojito: Cool off this summer with sweet blueberries, tart limes, and a refreshing splash of rum.


text:
« view all Gay Sitges • Hotels
Carrer de Joan Tarrida 16, Sitges, Spain
8.0 Good - based on 476 Agoda reviews
Why this hotel? Gay hotel. Popular sauna & bar. Great location. Free WiFi.more pictures / bigger pictures – click here
The Parrots Sitges gay hotel is 200 metres from the main gay beach and just a few steps from Parrots Pub, Central Bar Café and many of the most popular gay bars in Plaça Indústria.
Each simply furnished, comfortable en suite room is air-conditioned and features satellite TV, DVD player, safe and free WiFi.
Parrots Sauna is located within the hotel, as is Parrots Restaurant. Great value for money and a popular gay hotel that sells out quickly during peak season.
Small rooms - ok service
"If you really want to be in the middle of Sitges gay nightlife, then Parrots is great. Even has its own gay bar. However our room was small and for the price bracket, pretty basic. Service was friendly enough from start to finish. If they spent a bit of money bringing the hotel up to date it could be really good. (stayed Sept 2013)."
NW on 05-18-2014 | Problem with this review?
Reviews are the subjective opinion of a Travel Gay Europe user, not of Travel Gay Europe.
Your surname and email address will not be published.
We do not share your personal information with anyone else.
We check every review before publication.
You can read our moderation policy here.
Please enter your email address carefully. We may send you a verification request.
venue hotel
features bar, restaurant, sauna, sun terrace, free wi-fi
exclusively gay
customers Gaylast updated: 07-03-2016
By continuing to use the site, you agree to the use of cookies. (scroll to accept) more information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.


text:
In the morning, we will depart Los Angeles to arrive San Francisco, once there; we will head to Saint Mary Church, and then to Castro Street and Chinatown. We will sit for dinner before we drive the Bay Bridge and along the Treasure Island. Stay for overnight at Dublin.
We will pay UC Berkeley a visit exploring its Campus, and then strolling along the Campanile (Sather Tower). To Napa Valley we will be travelling for a visit to Sonoma winery, followed by a visit to the Redwood National Forest. The forest is home to the Tallest Trees in the world. Some of these trees are 2000 years old and growing to above 300 feet tall. Chandelier Tree, Tree Shop, Founder's Tree Grove and The Avenue of Giants are the most famous. Spend the night at Eureka.
From California we will head in the morning to Oregon. We will be traveling along Oregon's Coastline and will visit the oldest standing lighthouse on the Oregon Coast── Cape Blanco Lighthouse, a 245 feet above the ocean lighthouse. Portland will be our next destination. We will visit China Town, The Rose Test Garden and Duty Free stores, where you can find famous brands among them like Louis Vuitton, Tiffany Co., Rolex etc. Spend the night at Portland.
Today we will be at the Multnomah Falls exploring the United States second highest year round waterfall in the United States. Visitors reach two million per year. Afterwards, visit Crater Lake National Park; the lake was formed as a result of a volcanic eruption and the collapse of Mount Mazama 7,700 years ago. Stay at Klamath Falls for overnight.
Have your Breakfast before we head to the Lava Beds National Monument. Explore the lava tube caves and pit craters, before we head to Lake Shasta Caverns and have a cruise on the Lake Shasta. At Sundial Bridge we will then be. The bridge has a glass bottom and it is suitable for bicycle rides and pedestrians only. We will spend the night at the city of Reno.
We will be heading to Lake Tahoe. It's known mostly for hiking, camping & fishing, besides Skiing in winter. Next, we will move to San Francisco where we shall be having lunch and taking a tour around the city. You will be able to see the Golden Gate Bridge, Lombard Street, the Cable Car, Fisherman's Wharf and Palace of Fine Arts. Spend the night at Dublin.
From Dublin, we will proceed to Bear Mountain area to visit the Roaring Camp and walk among the redwood trees. You can also take the steam train (optional tour) for an hour.
Afterwards, we will head back to Los Angeles.
**Do not book any airline tickets until you receive your booking confirmation.**
Departure and Return Details
Departure Location
06:30 AM: 7709 Telegraph Rd, Montebello QUALITY INN & SUITES HOTEL ( HOTEL LOBBY ), CA 90640, Century Blvd, Los Angeles, CA 90045
06:30 AM: 99 Ranch Market, 5402 Walnut Ave, Irvine, Orange County, California 92604
06:30 AM: CONCOURSE HYATT hotel ( HOTEL LOBBY ) , 6225 WEST CENTURY BLVD
06:40 AM: Ramada Commerce Los Angeles Area, 7272 E Gage Ave, Commerce, CA 90040
07:00 AM: Bank of America, 850 N Broadway, Los Angeles, CA 90012
07:00 AM: Wells Fargo Bank, 9550 Bolsa Ave, Westminster, CA 92683
07:15 AM: Lincoln Plaza Hotel, 123 S Lincoln Ave, Monterey Park, CA 91755
07:30 AM: Hilton Los Angeles/San Gabriel, 225 W Valley Blvd, San Gabriel, CA 91776
08:00 AM: 99 Ranch Market, 1300 S Golden W Ave, Arcadia, CA 91007
08:00 AM: 99 Ranch Market, 17713 Pioneer Blvd, Artesia, CA 90701
08:30 AM: Class 302, 1015 Nogales St #125, Rowland Heights, CA 91748
Return Location
Extra Note
Entrance fees to various attractions are not included.


text:
Chris Horlacher brauchte ein neues Website Design und hat einen Wettbewerb auf 99designs gestartet.
Aus 20 Designs von 8 Designern wurde eine Gewinner gewählt.
Maple Leaf Metals Exchange is a newly formed bullion dealer in Canada. We will be selling physical gold, silver, platinum, palladium and rhodium to customers for investment and wealth preservation purposes.
We will be needing two page designs. A homepage and content page.
The homepage should be clean and professional looking, as well as serve as the central navigation hub for the website. I would like to have a news feed there, where I can put links to recent news stories as well as a price chart that will show the current spot prices of the metals we sell. It should also let users know of our flat-rate shipping policy ($30 shipping on all orders up to $100,000) and give users quick access to the other main areas of the website.
The content page will be used as a template to fill in each section page's content (About Us, Browse, About Bullion, FAQ and Contact sections that could each have multiple subsections that users can navigate to). It should retain the price chart because I would like to always have that displayed but can otherwise look however the designer feels is most attractive.
See the following link and scroll down to "SP-6" to see the chart that I would like included on the website and the instructions on how to embed it.


text:
The fragrance refill is suitable for hand soap Cranberry Dream for the No-Touch soap dispenser...更多
The fragrance refill is suitable for hand soap Cranberry Dream for the No-Touch soap dispenser from Dettol. The automatic soap dispenser recognizing words with its integrated motion sensor automatically your hands and dispenses seconds, the optimum amount Dettol hand soap. The soap in the scent Cranberry Dream eliminates 99.9% of bacteria and pampers the skin with lots of effective skin care substances.
- No-Touch Refill
- with lovely cranberry fragrance
- removed 99.9% of all bacteria
Use biocides safely.
Aqua, Cetrimonium chloride, Lauramine Oxide, Glycerin, PEG-150 Distearate, Cocamide MEA, Parfum, Citric Acid, Benzalkonium chloride, Tetrasodium Edetate, Sodium Chloride, Chloro-2-Methyl-4-Isothiazolin-3-one, Colorant, Limonene
Product specifications
1 x 250 ml SAGROTAN No Touch Handsoap Cranberry Dream


text:
Pork Pie Solid Quilted Maple Snare DrumProduct #447808 Pork Pie 447808 DAC Snare Drums https://www.esnapw.com/rses/ESnapServlet?MerchantNumberSent=63655
- Write a Review
- Seen a Lower Price? Click Here.
45 day price guarantee, 45 day return policy, 100% secure shopping
- Buy New
- Alerts
Item Note:
This product has been discontinued but may be available as a Open Box item.
Similar Items
The Pork Pie Solid Quilted Maple Snare will put you right into hog heaven!
This snare features a solid, one-piece quilted maple shell; solid brass, chrome-plated tube lugs; a Remo drumhead; and Pork Pie snare wires. Maple reinforcing rings add to shell stability.
Pork Pie's stunning attention to detail with the fit and finish round off this incredible drum. An intensive 11-part painting and polishing process give this drum a clear high-gloss finish to bring out the natural beauty of the wood for an incredible look.
- Maple reinforcing rings to aid shell stability
- Clear high-gloss finish
- Solid brass, chrome plated tube lugs
- Remo drumheads
An instant classic. Order today.